MCID: ERY017
MIFTS: 39

Erythema Elevatum Diutinum malady

Categories: Rare diseases, Skin diseases, Cardiovascular diseases, Bone diseases

Aliases & Classifications for Erythema Elevatum Diutinum

About this section
Sources:
11Disease Ontology, 30ICD10, 31ICD10 via Orphanet, 39MeSH, 40MESH via Orphanet, 48NIH Rare Diseases, 54Orphanet, 68UMLS, 69UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Erythema Elevatum Diutinum:

Name: Erythema Elevatum Diutinum 11 48 54 39 68

Characteristics:

Orphanet epidemiological data:

54
erythema elevatum diutinum:
Age of onset: All ages; Age of death: normal life expectancy

Classifications:



External Ids:

Disease Ontology11 DOID:0060567
ICD1030 L95.1
MeSH39 C535509
Orphanet54 ORPHA90000
ICD10 via Orphanet31 L95.1
MESH via Orphanet40 C535509
UMLS via Orphanet69 C0263398

Summaries for Erythema Elevatum Diutinum

About this section
NIH Rare Diseases:48 Erythema elevatum diutinum is a rare type of chronic cutaneous vasculitis characterized by red, purple, brown or yellow papules, plaques (thick, red patches of skin), or nodules.These lesions are located mainly on the knees, elbows, hands, feet, face, genitals and buttocks. Although it is a chronic condition, most cases respond well to treatment with dapsone. The cause of this condition remains unknown.  Last updated: 4/13/2010

MalaCards based summary: Erythema Elevatum Diutinum is related to vasculitis and arthritis, and has symptoms including skin rash, vasculitis and arthralgia. An important gene associated with Erythema Elevatum Diutinum is CXCL8 (C-X-C Motif Chemokine Ligand 8), and among its related pathways is Malaria. Affiliated tissues include skin, breast and bone.

Disease Ontology:11 A vasculitis characterised by red, purple, brown or yellow papules (raised spot), plaques, or nodules, found on the backs of the hands, other extensor surfaces overlying joints, and on the buttocks.

Wikipedia:71 Erythema elevatum diutinum is a form of vasculitis. more...

Related Diseases for Erythema Elevatum Diutinum

About this section

Graphical network of the top 20 diseases related to Erythema Elevatum Diutinum:



Diseases related to erythema elevatum diutinum

Symptoms & Phenotypes for Erythema Elevatum Diutinum

About this section

Human phenotypes related to Erythema Elevatum Diutinum:

 64 54 (show all 10)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 skin rash64 54 hallmark (90%) Very frequent (99-80%) HP:0000988
2 vasculitis64 hallmark (90%) HP:0002633
3 arthralgia64 54 hallmark (90%) Very frequent (99-80%) HP:0002829
4 abnormal blistering of the skin64 54 typical (50%) Frequent (79-30%) HP:0008066
5 abnormal immunoglobulin level64 typical (50%) HP:0010701
6 myalgia64 54 occasional (7.5%) Occasional (29-5%) HP:0003326
7 hypergammaglobulinemia54 Frequent (79-30%)
8 vasculitis in the skin54 Very frequent (99-80%)
9 skin nodule54 Occasional (29-5%)
10 skin vesicle54 Frequent (79-30%)

UMLS symptoms related to Erythema Elevatum Diutinum:


exanthema, eyelid erythema, erythematous ear canal, generalised erythema, umbilical erythema, instillation site erythema, incision site erythema

Drugs & Therapeutics for Erythema Elevatum Diutinum

About this section

Drugs for Erythema Elevatum Diutinum (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 241)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Heparinapproved, investigationalPhase 4, Phase 38129005-49-6772, 46507594
Synonyms:
101921-26-0
102-94-3
102785-31-9
104521-37-1
11078-24-3
11129-39-8
12656-11-0
2-o-sulfohexopyranuronosyl-(1->4)-2-deoxy-3-o-sulfo-2-(sulfoamino)hexopyranosyl-(1->4)-2-o-sulfohexopyranuronosyl-(1->4)-2-acetamido-2-deoxy-6-o-sulfohexopyranose
37324-73-5
6-[6-[6-[5-acetamido-4,6-dihydroxy-2-(sulfooxymethyl)oxan-3-yl]oxy-2-carboxy-4-hydroxy-5-sulfooxyoxan-3-yl]oxy-2-(hydroxymethyl)-5-(sulfoamino)-4-sulfooxyoxan-3-yl]oxy-3,4-dihydroxy-5-sulfooxyoxane-2-carboxylic acid
9041-08-1
9045-22-1
9075-96-1
913079-23-9
91449-79-5
AC1L19ZN
AC1L1ROY
ALFA 87-120
ALFA 87-163
ALFA 87-198
ALFA 87-81
ALFA 88-247
AR-1E4539
Allocinnamic acid
Ardeparin
Ardeparin sodium
Arteven
Bemiparin
Bemiparin sodium
CID772
CID8784
CY 216
Calciparine
Certoparin
Clexane
Clivarin
Clivarine
Cy 222
D006495
D017984
DB00407
DB01225
Dalteparin
Dalteparin sodium
Depo-Heparin
EINECS 232-681-7
EMT 966
EMT 967
EMT-966
EMT-967
EMT966
EMT967
Enoxaparin
Enoxaparin sodium
Enoxaparine
Eparina
Eparina [DCIT]
FR 860
Fluxum
Fragmin A
Fragmin B
Fragmin IV
Fraxiparin
H 2149
HSDB 3094
Hed-heparin
Hep Flush Kit in plastic container
Hep-Lock
Hep-Lock U/P
Hep-lock
Heparin
Heparin CY 216
Heparin Lock Flush
Heparin Lock Flush in plastic container
Heparin Lock Flush preservative free
Heparin Lock Flush preservative free in plastic container
Heparin Sodium
Heparin natrium
Heparin sodium
Heparin sodium 1,000 units and sodium chloride 0.9% in plastic container
Heparin sodium 1,000 units in dextrose 5% in plastic container
Heparin sodium 1,000 units in sodium chloride 0.9% in plastic container
Heparin sodium 10,000 units in dextrose 5%
Heparin sodium 10,000 units in dextrose 5% in plastic container
Heparin sodium 10,000 units in sodium chloride 0.45%
Heparin sodium 10,000 units in sodium chloride 0.9%
Heparin sodium 12,500 units in dextrose 5%
Heparin sodium 12,500 units in dextrose 5% in plastic container
Heparin sodium 12,500 units in sodium chloride 0.45% in plastic container
Heparin sodium 12,500 units in sodium chloride 0.9%
Heparin sodium 2,000 units and sodium chloride 0.9% in plastic container
Heparin sodium 2,000 units in dextrose 5% in plastic container
Heparin sodium 2,000 units in sodium chloride 0.9% in plastic container
Heparin sodium 20,000 units and dextrose 5% in plastic container
Heparin sodium 20,000 units in dextrose 5% in plastic container
Heparin sodium 25,000 units and dextrose 5% in plastic container
 
Heparin sodium 25,000 units in dextrose 5%
Heparin sodium 25,000 units in dextrose 5% in plastic container
Heparin sodium 25,000 units in sodium chloride 0.45% in plastic container
Heparin sodium 25,000 units in sodium chloride 0.9%
Heparin sodium 25,000 units in sodium chloride 0.9% in plastic container
Heparin sodium 5,000 units and sodium chloride 0.9% in plastic container
Heparin sodium 5,000 units in dextrose 5% in plastic container
Heparin sodium 5,000 units in sodium chloride 0.45%
Heparin sodium 5,000 units in sodium chloride 0.9%
Heparin sodium 5,000 units in sodium chloride 0.9% in plastic container
Heparin sodium in plastic container
Heparin sodium preservative Free
Heparin sulfate
Heparin sulphate
Heparin, Low Molecular Weight
Heparin, Low-Molecular-Weight
Heparin, sodium salt
Heparina
Heparina [INN-Spanish]
Heparinate
Heparine
Heparine [INN-French]
Heparinic acid
Heparinsodiumsalt
Heparinum
Heparinum [INN-Latin]
Heparinum natricum
Hepathrom
Hepflush-10
Inno-Hep
Innohep
Isocinnamic acid
KB 101
Kabi 2165
LHN 1
LMWH
Lioton 1000
Lipo-hepin
Liquaemin
Liquaemin Lock Flush
Liquaemin Sodium
Liquaemin sodium preservative free
Liquemin
Logiparin
Lovenox
Lovenox HP
Low Molecular Weight Heparin
Low molecular weight heparin
Low molecular weight heparin sodium
Low-Molecular-Weight Heparin
Minolteparin sodium
MolPort-003-760-257
Multiparin
NSC174025
Nadroparin
Nadroparine
Novoheparin
OP 386
OP 622
Octaparin
PK 10,169
PK-10,169
PK-10169
PK10,169
PK10169
Pabyrin
Panheprin
Parnaparin
Parnaparin sodium
Parvoparin
Pularin
Reviparin
Reviparin sodium
Ro 11
Sandoparin
Sodium acid heparin
Sodium heparin
Sodium heparinate
Subeparin
Sublingula
Thromboliquine
Tinzaparin
Tinzaparin sodium
Triofiban
UNII-12M44VTJ7B
UNII-3S182ET3UA
UNII-E47C0NF7LV
UNII-T2410KM04A
UNII-ZZ45AB24CA
Unfractionated heparin
Vetren
Vitrum AB
WY 90493RD
alpha-Heparin
cis-.beta.-Carboxystyrene
cis-Cinnamic acid
enoxaparin
heparin
2
MethotrexateapprovedPhase 4, Phase 3, Phase 215181959-05-2, 59-05-2126941
Synonyms:
4-amino-10-methylfolic acid
4-amino-N(10)-Methylpteroylglutamic acid
Abitrexate
Amethopterin
Amethopterine
Antifolan
Arbitrexate
Emtexate
Folex
HDMTX
L-Amethopterin
Ledertrexate
MTX
Metatrexan
 
Methopterin
Methotextrate
Methotrate
Methotrexat
Methotrexate Sodium
Methotrexatum
Methylaminopterin
Methylaminopterinum
Metotrexato
Mexate
Méthotrexate
N-Bismethylpteroylglutamic Acid
N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Rheumatrex
Trexall
3
MetforminapprovedPhase 4, Phase 31746657-24-914219, 4091
Synonyms:
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
3-(diaminomethylidene)-1,1-dimethylguanidine
657-24-9
AC1L1HE4
AKOS000121065
Apo-Metformin
BIDD:GT0697
BPBio1_000009
BRD-K79602928-003-04-1
BSPBio_000007
BSPBio_002314
C07151
C4H11N5
CAS-1115-70-4
CCRIS 9321
CHEBI:6801
CHEMBL1431
CID4091
D04966
DB00331
DMGG
Diabetosan
Diabex
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
EINECS 211-517-8
Fluamine
Flumamine
Fortamet
Gen-Metformin
Glifage
Gliguanid
Glucophage
Glucophage XR
Glumetza
Glycon
HMS2089D19
HSCI1_000295
Haurymelin
Haurymellin
Islotin
KBio2_002310
KBio2_004878
KBio2_007446
KBio3_002790
KBioGR_002310
 
KBioSS_002312
LA-6023
LS-43899
Melbin
Metformin
Metformin (USAN/INN)
Metformin HCL
Metformin [USAN:INN:BAN]
Metformina
Metformina [DCIT]
Metformina [Spanish]
Metformine
Metformine [INN-French]
Metformine pamoate
Metforminum
Metforminum [INN-Latin]
Metiguanide
MolPort-002-929-560
MolPort-004-288-389
MolPort-005-767-418
Mylan-Metformin
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylimidodicarbonimidic diamide
N,N-dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
NCGC00016564-01
NCGC00016564-02
NCGC00016564-03
NNDG
Novo-Metformin
Nu-Metformin
PMS-Metformin
Prestwick0_000004
Prestwick1_000004
Prestwick2_000004
Prestwick3_000004
Ran-Metformin
Ratio-Metformin
Riomet
S2483_Selleck
SPBio_001928
STK011633
Sandoz Metformin
Siofor
T5895664
Teva-Metformin
UNII-9100L32L2N
ZINC12859773
cMAP_000016
metformin
metformin hydrochloride
4
BudesonideapprovedPhase 442251333-22-363006, 5281004
Synonyms:
(11-beta,16-alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
(11beta,16alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
(4aR,4bS,5S,6aS,6bS,8R,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
(4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
(R,S)-11b,16a,17,21,tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with buty raldehyde
(RS)-(11beta,16alpha)-16,17-[Butylidenebis(oxy)]-11,21-dihydroxypregna-1,4-diene-3,20-dione
(RS)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butyraldehyde
(S)-16alpha,17-(Butylidenedioxy)-11beta,21-dihydroxypregna-1,4-diene-3,20-dione
11beta,21-dihydroxy-16alpha,17alpha-(butane-1,1-diyldioxy)pregna-1,4-diene-3,20-dione
16,17-Butylidenebis(oxy)-11,21-dihydroxypregna-1,4-diene-3,20-dione
16,17-Butylidenebis(oxy)-11-,21-dihydroxypregna-1,4-diene-3,20-dione
16-alpha,17-alpha-Butylidenedioxy-11-beta,21-dihydroxy-1,4-pregnadiene-3,20-dione
16alpha(R),17-(Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione
16alpha-,17alpha--butylidenedioxypregna-1,4-diene-11beta-,21-diol-3,20-dione
51333-22-3
AC-4697
AC1L1DQE
AC1L1Y6Y
AC1L22VC
AC1MHWI7
B 7777
B7777_SIGMA
BPBio1_000523
BRD-A34299591-001-03-4
BRD-A82238138-001-01-7
BSPBio_000475
BSPBio_002160
Bidien
Bio-0010
Budecort Inhaler
Budenofalk
Budeson
Budesonide (JAN/USAN/INN)
Budesonide Easyhaler
Budesonide MMX
Budesonide [USAN:INN:BAN:JAN]
Budesonido
Budesonido [INN-Spanish]
Budesonidum
Budesonidum [INN-Latin]
Budiair
Budicort
C25H34O6
CCRIS 5230
CHEBI:3207
CHEBI:656601
CHEMBL1370
CID2462
CID3033890
CID40000
CID5281004
CID63006
CPD000058337
Cortivent
D00246
DB01222
Desowen
Dexbudesonide
Dexbudesonide [INN]
DivK1c_000475
EINECS 257-139-7
EINECS 257-160-1
EINECS 257-161-7
EU-0100174
Entocort
Entocort EC
Entocort EC (TN)
Giona Easyhaler
HMS1569H17
HMS1921I22
HMS2094I13
HMS501H17
Horacort
 
IDI1_000475
Inflammide
KBio1_000475
KBio3_001660
KBioGR_001361
LS-187734
LS-7235
Lopac0_000174
MAP-0010
MLS000028507
MLS001077323
MLS002207112
Micronyl
Miflonide
MolPort-002-529-265
MolPort-003-666-332
MolPort-003-986-909
NCGC00015165-03
NCGC00021318-03
NCGC00021318-06
NCGC00089747-02
NCGC00089747-03
NCGC00089747-04
NCGC00178789-01
NINDS_000475
Noex
Preferid
Pregna-1,4-diene-3,20-dione, 16,17-butylidenebis(oxy)-11,21-dihydroxy-, (11beta,16alpha(R))-, and 16alpha,17-((S)-Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione
Prestwick0_000518
Prestwick1_000518
Prestwick2_000518
Prestwick3_000518
Prestwick_840
Pulmaxan
Pulmaxan turbohaler
Pulmicort
Pulmicort (TN)
Pulmicort Flexhaler
Pulmicort Nebuamp
Pulmicort Respules
Pulmicort Topinasal
Pulmicort Turbuhaler
Pulmicort turbuhaler
Respules
Rhinocort
Rhinocort Aqua
Rhinocort Turbuhaler
Rhinocort alpha
Rhinocort, Pulmicort , Entocort, Symbicort, Noex. Entocort EC, Budesonide
Rhinosol
S 1320
S-1320
S1286_Selleck
SAM002699898
SMR000058337
SPBio_000586
SPBio_002396
SPECTRUM1500813
ST51039033
Spectrum2_000623
Spectrum3_000620
Spectrum4_000821
Spectrum5_001738
Spirocort
TL8003397
Tridesilon
UDB
UNII-168L5HT37P
UNII-2HI1006KPH
UNII-Q3OKS62Q6X
Unit dose budesonide
ZINC03938751
ZINC04097286
budesonide
5
ZincapprovedPhase 4, Phase 322317440-66-632051, 23994
Synonyms:
30Zn
Cinc
Zinc
Zinc ion
 
Zincum
Zink
Zn
Zn(ii)
Zn2+
6
Insulin AspartapprovedPhase 4442116094-23-616132418
Synonyms:
(AspB28)-human insulin
1024611-56-0
116094-23-6
139532-40-4
28(sup B)-L-Aspartic acid-insulin (human)
877034-90-7
AspB28-insulin (human)
Aspart
Aspart Insulin
Aspart insulin
B28-Asp-insulin
B28-Aspart-Insulin
INA-X 14
 
INA-X14
Insulin X14
Insulin aspart
Insulin aspart [USAN]
Insulin aspart protamine recombinant
Insulin aspart recombinant
Insulin, Asp(B28)
LS-185932
NovoLog
NovoMix 30
NovoRapid
NovoRapid 30 Mix
Novolog mix 70/30
UNII-D933668QVX
7
Insulin-glulisineapprovedPhase 4104207748-29-6
Synonyms:
 
Insulin Glulisine (recombinant DNA origin)
Insulin glulisine recombinant
8
Insulin GlargineapprovedPhase 4522160337-95-1
Synonyms:
 
Insulin Glargine (rDNA origin)
Insulin glargine recombinant
9
CanagliflozinapprovedPhase 4107842133-18-0
Synonyms:
 
Canagliflozin anhydrous
10
GoserelinapprovedPhase 422965807-02-547725, 5311128
Synonyms:
(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
AC1NSK1T
CID5311128
Goserelin
Goserelin acetate
 
HMS2089D16
HS-2015
ICI-118630
MolPort-006-823-831
ZD-9393
Zoladex
goserelin
11
Leuprolideapproved, investigationalPhase 429353714-56-03911, 657181
Synonyms:
(D-Leu(6),des-gly-NH2(10),pro-ethylamide(9))-gonadotropin-releasing hormone
5-oxoPro-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-ProNHC2H5 dihydrate
5-oxoprolylhistidyltryptophylseryltyrosylleucylleucyl-n5-(diaminomethylidene)ornithyl-n-ethylprolinamide
AC1L1GZK
AC1L9B44
AC1Q5OPO
AR-1G9354
C07612
CID3911
CID441410
D00989
D08113
Enantone
Enantone (TN)
I04-0109
L-Pyroglutamyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-L-proline ethylamide
L001094
 
L002030
Leuprolide
Leuprolide acetate
Leuprolide acetate (USAN)
Leuprorelin
Leuprorelin (INN)
Leuprorelin acetate (JAN)
Leuprorelina
Leuproreline
Leuprorelinum
Lupron (TN)
N-[1-[[1-[[1-[[1-[[1-[[1-[[5-(diaminomethylideneamino)-1-[2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
NSC377526
NSC746847
PGlu-his-trp-ser-tyr-D-leu-leu-arg-pro-NHC2H5
PGlu-his-trp-ser-tyr-D-leu-leu-arg-pro-nhet
acetic acid
leuprolide
12
Folic Acidapproved, nutraceutical, vet_approvedPhase 4, Phase 3, Phase 2427959-30-36037
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
AI3-26387
AKOS000503224
ARONIS014410
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
Antianemia factor
Apo-Folic
BIDD:ER0563
BIDD:GT0641
BIF0608
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
FOL
Facid
Factor U
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
Folipac
Folsaeure
 
Folsan
Folsaure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
Incafolic
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
LS-2157
Liver Lactobacillus casei factor
MLS001304016
MLS001335861
Millafol
Mission prenatal
Mittafol
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-Pteroyl-L-glutamic acid
N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
NINDS_000494
NSC 3073
Nifolin
Nifolin [Denmark]
Novofolacid
Novofolacid [Canada]
PGA
PGA (VAN)
Prestwick3_000627
Prestwick_230
PteGlu
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylglutamate
Pteroylglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
SMP2_000137
SMR000471860
SPBio_001357
SPECTRUM1502020
Serum Folate Level
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
Spectrum_001381
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin B9
Vitamin Bc
Vitamin Be
Vitamin M
bmse000299
folic acid
nchembio.108-comp10
13Vitamin B ComplexPhase 4, Phase 3, Phase 24229
14Antineoplastic Agents, HormonalPhase 4, Phase 3, Phase 25407
15Contraceptive AgentsPhase 4, Phase 31901
16Immunosuppressive AgentsPhase 4, Phase 3, Phase 212770
17Folic Acid AntagonistsPhase 4, Phase 3, Phase 22200
18Antirheumatic AgentsPhase 4, Phase 3, Phase 210627
19Antimetabolites, AntineoplasticPhase 4, Phase 3, Phase 27171
20AntimetabolitesPhase 4, Phase 3, Phase 211774
21Dermatologic AgentsPhase 4, Phase 3, Phase 25674
22Nucleic Acid Synthesis InhibitorsPhase 4, Phase 3, Phase 24855
23Hormone AntagonistsPhase 4, Phase 3, Phase 212778
24calcium heparinPhase 4, Phase 3812
25HormonesPhase 4, Phase 3, Phase 213979
26Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 3, Phase 212767
27Formoterol FumaratePhase 4424
28glucocorticoidsPhase 4, Phase 3, Phase 24920
29Hypoglycemic AgentsPhase 4, Phase 35733
30Neurotransmitter AgentsPhase 4, Phase 3, Phase 217734
31Budesonide, Formoterol Fumarate Drug CombinationPhase 4166
32Anti-Inflammatory AgentsPhase 4, Phase 3, Phase 210355
33Anti-Asthmatic AgentsPhase 4, Phase 33369
34Autonomic AgentsPhase 4, Phase 3, Phase 29774
35Bronchodilator AgentsPhase 4, Phase 32856
36Adrenergic AgentsPhase 4, Phase 35140
37Adrenergic beta-2 Receptor AgonistsPhase 4925
38Adrenergic beta-AgonistsPhase 41640
39Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 222776
40CoagulantsPhase 41428
41Insulin, Globin ZincPhase 4, Phase 34523
42Insulin, Long-ActingPhase 4, Phase 3358
43Insulin degludec, insulin aspart drug combinationPhase 4248
44insulinPhase 4, Phase 34524
45Adrenergic AgonistsPhase 4, Phase 32877
46Insulin aspart, insulin aspart protamine drug combination 30:70Phase 4106
47LaxativesPhase 4520
48Biphasic InsulinsPhase 4155
49CatharticsPhase 4520
50Gastrointestinal AgentsPhase 4, Phase 3, Phase 28109

Interventional clinical trials:

(show top 50)    (show all 80)
idNameStatusNCT IDPhase
1Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX® as Compared to SYMBICORT® TURBOHALER® as Treatment for Adult Patients With AsthmaCompletedNCT02062463Phase 4
2Comparison of a Basal Plus One Insulin Regimen With a Biphasic Insulin Regimen in Type 2 Diabetes PatientsCompletedNCT00965549Phase 4
3Local Phase 4 Pan-European SMART StudyCompletedNCT00463866Phase 4
4AQUACEL® Ag Dressing and Urgotul® Silver Dressing on Healing of Chronic Venous Leg UlcersCompletedNCT01084577Phase 4
5A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes MellitusActive, not recruitingNCT01989754Phase 4
6A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Severe Active Rheumatoid Arthritis, Comparing Tapering Versus Maintaining the Methotrexate DosageTerminatedNCT01661140Phase 4
7GP Extended Action TriptorelinTerminatedNCT01673984Phase 4
8Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine for Advanced Colorectal Cancer or Breast CancerUnknown statusNCT00559858Phase 3
9Intensity-Modulated Radiation Therapy in Treating Patients With Localized Prostate CancerUnknown statusNCT00392535Phase 3
10Dalteparin in Preventing Blood Clots in Patients With Lung CancerUnknown statusNCT00519805Phase 3
11Combination Chemotherapy With or Without Cetuximab as First-Line Therapy in Treating Patients With Metastatic Colorectal CancerUnknown statusNCT00182715Phase 3
12Apixaban for the Prevention of Stroke in Subjects With Atrial FibrillationCompletedNCT00412984Phase 3
13A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular DiseaseCompletedNCT00501059Phase 3
14A Study of Sativex® for Relieving Persistent Pain in Patients With Advanced CancerCompletedNCT01262651Phase 3
15High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia PreventionCompletedNCT01355159Phase 3
16A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C. Difficile-Associated DiarrheaCompletedNCT00196794Phase 3
17A Study of RoActemra/Actemra (Tocilizumab) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF CompletedNCT02046603Phase 3
18Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential HypertensionCompletedNCT01788358Phase 3
19Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated RiskCompletedNCT01764633Phase 3
20A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced CancerCompletedNCT01424566Phase 3
21Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 DiabetesCompletedNCT01336023Phase 3
22Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary DiseaseCompletedNCT01313676Phase 3
23An Extension to Study MA21573, Evaluating Tocilizumab in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biological DMARDs and/or Anti-tumor Necrosis Factor (TNF) TherapyCompletedNCT00883753Phase 3
24An Exploratory Study of Tocilizumab in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Current Non-Biologic DMARDs and/or Anti-TNF Therapy.CompletedNCT00750880Phase 3
25Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DMCompletedNCT00736099Phase 3
26Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes PatientsCompletedNCT00660907Phase 3
27BI 1356 (Linagliptin) in Combination With Metformin and a Sulphonylurea in Type 2 DiabetesCompletedNCT00602472Phase 3
28Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00400153Phase 3
29A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon CancerCompletedNCT00069121Phase 3
30Dexmedetomidine Versus Propofol for Continuous Sedation in the Intensive Care Unit (ICU)CompletedNCT00479661Phase 3
31A Randomised Placebo Controlled Study of OXN PR for Severe Parkinson's Disease Associated PainCompletedNCT01439100Phase 3
32Long Term Safety of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related PainCompletedNCT01337089Phase 3
33A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With BortezomibCompletedNCT01324596Phase 3
34Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary EmbolismCompletedNCT00633893Phase 3
35Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromesCompletedNCT00454480Phase 2, Phase 3
36Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid TumoursRecruitingNCT02804815Phase 3
37A Study to Assess the Efficacy and Safety of the Gastric-retentive AP-CD/LD in Advanced Parkinson's PatientsRecruitingNCT02605434Phase 3
38An Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's DiseaseRecruitingNCT02542696Phase 3
39Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)RecruitingNCT02540954Phase 3
40Open-Label Extension and Safety Study for Patients With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144RecruitingNCT02403323Phase 3
41A Study of the Safety and Efficacy of Etrolizumab in Patients With Moderately to Severely Active Crohn's DiseaseRecruitingNCT02394028Phase 3
42A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Patients With Moderate to Severe Ulcerative Colitis Who Are Naive to TNF InhibitorsRecruitingNCT02136069Phase 3
43Open-label Extension and Safety Study for Patients With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase III StudiesRecruitingNCT02118584Phase 3
44A Study of the Efficacy and Safety of Etrolizumab in Ulcerative Colitis Participants Who Are Refractory to or Intolerant of Tumor Necrosis Factor (TNF) InhibitorsRecruitingNCT02100696Phase 3
45STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled TrialRecruitingNCT00268476Phase 2, Phase 3
46A Study to Compare ABT-494 to Placebo in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDsRecruitingNCT02706847Phase 3
47Rituximab in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's LymphomaActive, not recruitingNCT00112931Phase 3
48Combination Chemotherapy in Treating Patients With Early Stage Breast Cancer That Has Been Removed By SurgeryActive, not recruitingNCT00301925Phase 3
49Multi-centre UK Study of the Acetylcholinesterase Inhibitor Donepezil in Early Dementia Associated With Parkinson's DiseaseSuspendedNCT01014858Phase 3
50Rapid Versus Conventional Titration of Quetiapine in Schizophrenia/Schizoaffective DisorderTerminatedNCT00457899Phase 3

Search NIH Clinical Center for Erythema Elevatum Diutinum


Cochrane evidence based reviews: erythema elevatum diutinum

Genetic Tests for Erythema Elevatum Diutinum

About this section

Anatomical Context for Erythema Elevatum Diutinum

About this section

MalaCards organs/tissues related to Erythema Elevatum Diutinum:

36
Skin, Breast, Bone, B cells, Prostate, Neutrophil, Liver

Publications for Erythema Elevatum Diutinum

About this section

Articles related to Erythema Elevatum Diutinum:

(show top 50)    (show all 183)
idTitleAuthorsYear
1
A rare case of erythema elevatum diutinum presenting as diffuse neuropathy. (28050587)
2017
2
Pediatric case of microscopic polyangiitis with skin manifestations resembling vesiculobullous type erythema elevatum diutinum with immunoglobulin A antineutrophil cytoplasmic antibody. (27097593)
2016
3
Erythema elevatum diutinum in acquired immune deficiency syndrome: Can it be an immune reconstitution inflammatory syndrome? (27190420)
2016
4
Chronic Localized Fibrosing Leukocytoclastic Vasculitis Associated With Lymphedema, Intralymphatic and Intravascular Lymphocytosis, and Chronic Myelogenous Leukemia: A Case Report of Unilateral Erythema Elevatum Diutinum. (27930381)
2016
5
Erythema elevatum diutinum in association with IgA monoclonal gammopathy: A rare case report. (27559509)
2016
6
Granuloma Faciale and Erythema Elevatum Diutinum in Relation to Immunoglobulin G4-Related Disease: An Appraisal of 32 Cases. (27124923)
2016
7
A case of mistaken identity: unilateral erythema elevatum diutinum associated with IgA paraproteinaemia. (25754401)
2015
8
Erythema elevatum diutinum and hypothyroidism: coincidence or causal relationship? (26375227)
2015
9
Erythema elevatum diutinum: an atypical presentation. (25521326)
2015
10
A Case of Erythema Elevatum Diutinum With Pancytopenia: Focus on Dapsone-Induced Hematologic Side Effects and Colchicine as a Safe Treatment Option. (26461818)
2015
11
Erythema elevatum diutinum coexisting with ankylosing spondylitis. (27708930)
2015
12
An atypical distribution of erythema elevatum diutinum. (24479627)
2014
13
Erythema elevatum diutinum in association with dermatitis herpetiformis. (24616856)
2014
14
Erythema Elevatum Diutinum (EED): A Distinctive Vasculitis with Acute-on-Chronic Features. (24652434)
2014
15
An unusual case of Sweet syndrome in a child: overlapping presentation with erythema elevatum diutinum. (24521734)
2014
16
Erythema elevatum diutinum: a review of presentation and treatment. (25288365)
2014
17
Nodular Erythema Elevatum Diutinum Mimicking Kaposi's Sarcoma in a Human Immunodeficiency Virus Infected Patient. (25484391)
2014
18
Case of Erythema Elevatum Diutinum Associated With IgA Paraproteinemia Successfully Controlled With Thalidomide and Plasma Exchange. (25257541)
2014
19
An unusual case of erythema elevatum diutinum with penile and laryngeal manifestations. (24413401)
2014
20
Erythema elevatum diutinum. (23487831)
2013
21
Associated pyoderma gangrenosum, erythema elevatum diutinum, and Sweet's syndrome: the concept of neutrophilic disease. (24073904)
2013
22
Erythema elevatum diutinum. (23442466)
2013
23
Novel use of topical dapsone 5% gel for erythema elevatum diutinum: safer and effective. (23652900)
2013
24
Erythema elevatum diutinum: a new vesiculobullous case. (24001509)
2013
25
Atypical erythema elevatum diutinum or extrafacial granuloma faciale? (23253514)
2013
26
Erythema elevatum diutinum with oral ulceration. (22284024)
2012
27
Successful combination therapy with dapsone and cyclosporine for erythema elevatum diutinum with unusual appearance. (22132683)
2012
28
A case of erythema elevatum diutinum associated with peripheral ulcerative keratitis. (22309340)
2012
29
Alternative procedure to allow continuation of dapsone therapy despite serious adverse reaction in a case of dapsone-sensitive erythema elevatum diutinum. (22508198)
2012
30
Erythema elevatum diutinum mimicking a vesiculobullous disease. (22126877)
2011
31
Erythema elevatum diutinum associated with scleritis. (23130212)
2011
32
Erythema elevatum diutinum associated with dermatomyositis. (21496713)
2011
33
Erythema elevatum diutinum - a chronic leukocytoclastic vasculitis microscopically indistinguishable from granuloma faciale? (21883365)
2011
34
Erythema elevatum diutinum associated with peripheral ulcerative keratitis. (20569285)
2011
35
Erythema elevatum diutinum: an "idiopathic" case. (21810392)
2011
36
A case of extensive erosive and bullous erythema elevatum diutinum in a patient diagnosed with human immunodeficiency virus (HIV). (21781074)
2011
37
Is IgA antineutrophil cytoplasmic antibody a marker for patients with erythema elevatum diutinum? A further three cases demonstrating this association. (21143463)
2011
38
Dapsone Hypersensitivity Syndrome That Occurred during Treatment of Pediatric Patient with Erythema Elevatum Diutinum. (22346260)
2011
39
Progressive keratolysis with pseudopterygium associated with erythema elevatum diutinum. (21211842)
2011
40
Erythema elevatum diutinum in systemic lupus erythematosus. (20652813)
2011
41
Acceleration of pulmonary interstitial fibrosis in a patient with myeloperoxidase-antineutrophil cytoplasmic antibody-positive erythema elevatum diutinum. (21839335)
2011
42
Erythema elevatum diutinum with verrucous carcinoma: a rare association. (20657132)
2010
43
Successful surgical treatment of advanced erythema elevatum diutinum. (21358872)
2010
44
Erythema elevatum diutinum in association with celiac disease. (19570095)
2009
45
Erythema elevatum diutinum presenting with a giant annular pattern. (19261019)
2009
46
Erythema elevatum diutinum as a paraneoplastic syndrome in a patient with pulmonary lymphoepithelioma-like carcinoma. (18571759)
2009
47
An atypical presentation of erythema elevatum diutinum involving palms and soles. (19126056)
2009
48
Photoclinic. Erythema elevatum diutinum. (18759532)
2008
49
Erythema elevatum diutinum with unusual clinical appearance. (18266859)
2008
50
Erythema elevatum diutinum. (19061612)
2008

Variations for Erythema Elevatum Diutinum

About this section

Expression for genes affiliated with Erythema Elevatum Diutinum

About this section
Search GEO for disease gene expression data for Erythema Elevatum Diutinum.

Pathways for genes affiliated with Erythema Elevatum Diutinum

About this section

Pathways related to Erythema Elevatum Diutinum according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
19.3CXCL8, PECAM1

GO Terms for genes affiliated with Erythema Elevatum Diutinum

About this section

Biological processes related to Erythema Elevatum Diutinum according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1platelet degranulationGO:00025769.1F13A1, PECAM1

Sources for Erythema Elevatum Diutinum

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet